Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Journal of Psychopharmacology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Lader, M. H.
Right arrow Articles by Morton, S. V.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Lader, M. H.
Right arrow Articles by Morton, S. V.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

A pilot study of the effects of flumazenil on symptoms persisting after benzodiazepine withdrawal

Malcolm H. Lader

Institute of Psychiatry, De Crespigny Park, Denmark Hill, London SE5 8AF, UK

Sally V. Morton

Institute of Psychiatry, De Crespigny Park, Denmark Hill, London SE5 8AF, UK

The potential of the benzodiazepine antagonist flumazenil (Ro 15-1788) to lessen persisting benzodiazepine withdrawal symptoms was demonstrated in 11 patients who had been drug free for between 1 month and 5 years. Doses ranging from 0.2 to 2.0 mg divided into three intravenous injections over a few hours relieved long-standing symptoms to varying extents. These included clouded thinking, tiredness, muscular symptoms such as neck tension, cramps and shaking and the characteristic perceptual symptoms of benzodiazepine withdrawal, namely, pins and needles, burning skin, pain and subjective sensations of bodily distortion. Mood disorder, when present, also improved but the reduction in anxiety and depression may have reflected relief of physical symptoms. The onset of maximum response was sometimes delayed by as much as a day but was usually prompt. Side effects were reported to be either absent or typically described as lightheadedness or dizziness, lasted only a few minutes and were usually well tolerated. The benefits last between a few hours and several days despite flumazenil's otherwise short duration of action. However, symptoms did return to varying degrees in most cases, suggesting the need for repeated doses.

Key Words: flumazenil • benzodiazepine withdrawal • benzodiazepine antagonist

Journal of Psychopharmacology, Vol. 6, No. 3, 357-363 (1992)
DOI: 10.1177/026988119200600303


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J PsychopharmacolHome page
H. Ashton, A. H. Young, and N. Ferrier
Psychopharmacology revisited
J Psychopharmacol, May 1, 1999; 13(3): 296 - 298.
[PDF]


Home page
J PsychopharmacolHome page
P.E. Harrison-Read, P. Tyrer, C. Lawson, S. Lack, C. Fernandes, and S.E. File
Flumazenil-precipitated panic and dysphoria in patients dependent on benzodiazepines: a possible aid to abstinence
J Psychopharmacol, January 1, 1996; 10(2): 89 - 97.
[Abstract] [PDF]


Home page
J PsychopharmacolHome page
M. H. Lader
Commentary on 'Flumazenil-precipitated panic and dysphoria in patients dependent on benzodiazpines: a possible aid to abstinence'
J Psychopharmacol, January 1, 1996; 10(2): 98 - 98.
[PDF]



Advertisement